Pharmacology, Toxicology and Pharmaceutics, Pharmacy, Pharmacology
3
Scopus Publications
1
Scholar Citations
1
Scholar h-index
Scopus Publications
Rifampin-induced bullous pemphigoid in tuberculosis treatment: A strategic rechallenge approach Vaishnavi V Gaonkar, Vinay V Shanbhag, Mandati Santhosh Reddy, Pratiksha Kini, Bhavana Doshi American Journal of Health System Pharmacy, 2026 Purpose The purpose of this case report is to highlight an unusual presentation of rifampin-induced bullous pemphigoid in a 37-year-old female undergoing tuberculosis treatment. The report aims to explore the challenges of managing drug-induced bullous pemphigoid while maintaining effective treatment for tuberculosis, emphasizing the necessity of a strategic approach to drug management and disease control. Summary A 37-year-old female with tuberculosis developed an atypical form of bullous pemphigoid during rifampin therapy. The patient presented with painful, pruritic vesicular lesions that directly manifested as bullous lesions without the typical prodromal phase and without mucosal involvement. Histopathological examination confirmed the diagnosis with subepidermal blisters and eosinophilic infiltration. Management of this case involved carefully balancing tuberculosis treatment with bullous pemphigoid control, which required a modified rechallenge protocol, dose titration of rifampin, and a combination of systemic corticosteroids, immunomodulators, and supportive care. Conclusion This case underscores the complexity of managing drug-induced bullous pemphigoid in patients undergoing treatment for tuberculosis. The successful outcome was achieved through a cautious approach, including a rechallenge protocol and careful drug dose adjustments. The case offers valuable insights for clinicians managing similar complex presentations of drug-induced bullous pemphigoid, demonstrating that, with a tailored treatment strategy, both conditions can be effectively controlled.
Impact of proton pump inhibitors on clinical outcomes and adverse drug reactions in antiplatelet therapy: A prospective study from an Indian hospital Mandati Santhosh Reddy, M. S. Ganachari, Pratiksha Kini International Journal of Risk and Safety in Medicine, 2026 Background Coronary artery disease (CAD) management relies on antiplatelet therapy to prevent atherothrombotic events but increases gastrointestinal (GI) bleeding risk. Proton pump inhibitors (PPIs) are recommended for gastroprotection, though their effect on cardiovascular outcomes remains debated. Objectives To evaluate the impact of PPI co-therapy on GI bleeding, cardiovascular events, adverse drug reactions (ADRs), and drug–drug interactions (DDIs) in patients on mono or dual antiplatelet therapy. Methods A prospective observational study was conducted over 4 months in a tertiary care hospital. Patients on mono (MAPT) or dual antiplatelet therapy (DAPT), with or without PPIs, were included. Data on demographics, clinical outcomes, ADRs, and DDIs were analyzed. Results Of 174 patients, 48 received DAPT + PPI, 62 DAPT only, 34 MAPT + PPI, and 30 MAPT only. GI bleeding incidence was lower in PPI groups (DAPT + PPI: 6.25%, MAPT + PPI: 2.9%) versus non-PPI groups (DAPT only: 21%, MAPT only: 13.3%). Cardiovascular outcomes were unaffected (Myocardial Infarction: 27.1% vs 38.7% in DAPT + PPI vs DAPT only). 91 ADRs were reported, mainly GI bleeding (23.1%) and dyspnea (16.5%). Major DDIs included aspirin + clopidogrel (24.8%) and aspirin + ticagrelor (17.3%). Conclusion PPI co-prescription significantly reduced GI bleeding without compromising cardiovascular outcomes, supporting guideline-based prophylaxis in CAD patients receiving antiplatelet therapy.
From reaction to reporting: Impact of pharmacovigilance in a tertiary care hospital setting at Belagavi Pratiksha Kini, Mandati Santhosh Reddy, MS Ganachari International Journal of Risk and Safety in Medicine, 2025 Background Adverse drug reactions (ADRs) pose significant risks to patient safety, particularly in tertiary care settings characterized by polypharmacy and multiple comorbidities. Monitoring and evaluating ADRs is vital to improving therapeutic outcomes and minimizing harm. Objective This study aimed to assess the pattern, severity, predictability, seriousness, and causality of ADRs reported in a tertiary care teaching hospital in Belagavi, India. Methods A prospective observational study was conducted on 2035 spontaneously reported ADRs collected between January and December 2024 at the Adverse Drug Reaction Monitoring Centre under the Pharmacovigilance Programme of India (PvPI). Data were analyzed using the WHO-UMC causality assessment, Hartwig and Siegel severity scale, and standard classifications for seriousness and predictability. Results Adults (60.54%) and elderly (24.67%) were most frequently affected. Gastrointestinal disorders (23.91%) were the most commonly reported System Organ Class (SOC). Most ADRs were predictable (87.81%) and probable in causality (67.91%). Severe ADRs accounted for 15.97%. Vomiting and headache were the most reported adverse events. Antiretroviral were the most commonly implicated drug class. Conclusion The majority of ADRs were predictable and involved widely used drug classes. Strengthening pharmacovigilance practices and implementing targeted clinical interventions are essential to prevent avoidable ADRs and improve patient safety.
RECENT SCHOLAR PUBLICATIONS
Impact of proton pump inhibitors on clinical outcomes and adverse drug reactions in antiplatelet therapy: A prospective study from an Indian hospital MS Reddy, MS Ganachari, P Kini International Journal of Risk & Safety in Medicine, 09246479261430590 , 2026 2026
Rifampin-induced bullous pemphigoid in tuberculosis treatment: A strategic rechallenge approach VV Gaonkar, VV Shanbhag, MS Reddy, P Kini, B Doshi American Journal of Health-System Pharmacy 83 (3), e99-e104 , 2026 2026
From reaction to reporting: Impact of pharmacovigilance in a tertiary care hospital setting at Belagavi P Kini, MS Reddy, MS Ganachari International Journal of Risk & Safety in Medicine 36 (4), 281-288 , 2025 2025
Utilization of NCCMERP Index to Assess and Categorize Medication Discrepancies among Pediatric Patients: A Hospital Based Epileptic Cohort Study VP ,S Wali, M Gudhoor, Pratiksha Kini, M S Ganachari,V Byakod International journal of Pharmaceutical Investigation 16 (1), 241-251 , 2025 2025
Predictability, Severity and Causality Assessment of Adverse Drug Reactions Reported at a Tertiary Care Hospital in Belagavi, North Karnataka: A Prospective Observational Study. MS Reddy, PN Kini, MS Ganachari International Journal of Pharmaceutical Investigation 15 (3) , 2025 2025 Citations: 1
Transverse Leukonychia (Mees Lines) in Pediatric T-cell Acute Lymphoblastic Leukemia a Rare Manifestation During Combination Chemotherapy’s Maintenance Phase: A Case Report M Gudhoor, S Kumaresh, A Sampagar, A Doddannavar, G Wakkundmath, ... Journal of Young Pharmacists 16 (4), 852-855 , 2024 2024
Impact of clinical onco-pharmacist interventions on quality of life in pediatric cancer patients: A paired-t test analysis P Kini, G Manjula, MN Mullur, MS Ganachari Pediatric Hematology Oncology Journal 9 (4), S67 , 2024 2024
MOST CITED SCHOLAR PUBLICATIONS
Predictability, Severity and Causality Assessment of Adverse Drug Reactions Reported at a Tertiary Care Hospital in Belagavi, North Karnataka: A Prospective Observational Study. MS Reddy, PN Kini, MS Ganachari International Journal of Pharmaceutical Investigation 15 (3) , 2025 2025 Citations: 1
Impact of proton pump inhibitors on clinical outcomes and adverse drug reactions in antiplatelet therapy: A prospective study from an Indian hospital MS Reddy, MS Ganachari, P Kini International Journal of Risk & Safety in Medicine, 09246479261430590 , 2026 2026
Rifampin-induced bullous pemphigoid in tuberculosis treatment: A strategic rechallenge approach VV Gaonkar, VV Shanbhag, MS Reddy, P Kini, B Doshi American Journal of Health-System Pharmacy 83 (3), e99-e104 , 2026 2026
From reaction to reporting: Impact of pharmacovigilance in a tertiary care hospital setting at Belagavi P Kini, MS Reddy, MS Ganachari International Journal of Risk & Safety in Medicine 36 (4), 281-288 , 2025 2025
Utilization of NCCMERP Index to Assess and Categorize Medication Discrepancies among Pediatric Patients: A Hospital Based Epileptic Cohort Study VP ,S Wali, M Gudhoor, Pratiksha Kini, M S Ganachari,V Byakod International journal of Pharmaceutical Investigation 16 (1), 241-251 , 2025 2025
Transverse Leukonychia (Mees Lines) in Pediatric T-cell Acute Lymphoblastic Leukemia a Rare Manifestation During Combination Chemotherapy’s Maintenance Phase: A Case Report M Gudhoor, S Kumaresh, A Sampagar, A Doddannavar, G Wakkundmath, ... Journal of Young Pharmacists 16 (4), 852-855 , 2024 2024
Impact of clinical onco-pharmacist interventions on quality of life in pediatric cancer patients: A paired-t test analysis P Kini, G Manjula, MN Mullur, MS Ganachari Pediatric Hematology Oncology Journal 9 (4), S67 , 2024 2024
